Determinación de la capacidad antioxidante de vinos tintos. Efecto de la maceración con subproductos de la industria enológica

La uva es una de las frutas con mayor producción en el mundo, debido a que cada año se elaboran millones de hectolitros de vino. Por lo tanto, es de interés estudiar el efecto en la salud del vino tinto y su posible optimización. Los compuestos fenólicos del vino tinto son los responsables de su capacidad antioxidante y, por lo tanto, son los principales implicados en los beneficios en la salud que proporciona el vino. Las semillas procedentes del orujo, uno de los subproductos de la industria enológica, siguen conservando polifenoles tras la vinificación y es posible utilizarlas para mejorar las características antioxidantes del vino tinto. En este trabajo se han evaluado varios parámetros en muestras de vino tinto de Syrah a los que se les han añadido semillas durante la vinificación (Corto: adición de semillas una vez; Largo: adición de semillas en dos ocasiones). Se ha evaluado el contenido medio en fenoles totales mediante el método de Folin Ciocalteau y la capacidad antioxidante mediante los métodos ABTS y FRAP. El vino al que se le adiciona 12 gr/L de semillas en una sola fecha (Corto) presenta valores significativamente mayores (p<0,05) de polifenoles totales con respecto a los valores del vino Testigo (1725 y 1019 mg/L respectivamente). Los resultados obtenidos en cuanto a la capacidad antioxidante fueron significativamente más elevados en los vinos del ensayo Largo con respecto a los vinos Corto y Testigo (1893, 1181 y 867 μmoles TE/L respectivamente). En el caso del FRAP, los vinos elaborados con adición de semillas (Corto y Largo) presentaron valores más elevados de capacidad antioxidante que los elaborados sin adición (Testigo).Universidad de Sevilla. Grado en Farmaci

La segregación ocupacional y sectorial de la mujer en el mercado de trabajo español.

La concentración de las mujeres y los hombres en diferentes ocupaciones constituye un hecho empírico fundamental de la distribución del empleo. Es, además, uno de los campos más significativos en los que se manifiesta la desigualdad de género en el mercado de trabajo y, asimismo, está estrechamente relacionada con la desigualdad salarial entre hombres y mujeres existente en el mercado de trabajo. La observación de elevados niveles de segregación ocupacional de género a lo largo del último siglo ha suscitado el interés de una serie de economistas y sociólogos por el estudio de este tema, a partir de cuyas aportaciones ha ido surgiendo una importante literatura tanto empírica como teórica (véase, por ejemplo, Beller 1982; Karmel y Maclachlan 1988; Blau, Simpson y Anderson 1998; y en España Maté, Nava y Rodríguez 2001) . Respecto de esta última, se puede decir que el fundamento teórico del fenómeno de la segregación ocupacional y sectorial de género se puede encontrar, entre otras, en la teoría del capital humano (Brown y Corcoran 1997); en las versiones del modelo de preferencia por la discriminación de Becker (1957) en las que, o bien los empleados o bien los clientes de la empresa tienen prejuicios respecto del trabajo femenino; en el “modelo del amontonamiento” (crowding model) de Bergmann (1986); o en la teoría del mercado de trabajo dual (Goldin 1986, y Bulow y Summers1986). Este interés se complementa con la creciente preocupación de las autoridades políticas por desarrollar políticas públicas encaminadas a combatir las desigualdades de género en el mercado de trabajo. En este contexto, el objetivo del presente trabajo es el análisis de la segregación de género por ocupaciones y por sectores en España, a partir de la Encuesta de la Población Activa (EPA). Cabe destacar, en este sentido, que en este trabajo -a diferencia de la mayoría de estudios sobre esta materia- el análisis de la segregación ocupacional de género se complementa con el de la segregación sectorial de género, debido a que la serie homogénea disponible para los sectores (1987-2001) abarca un período más amplio que la correspondiente a las ocupaciones (1994-2001). El esquema que se va a seguir es el siguiente: en primer lugar, se examinan los cuadros y los gráficos correspondientes a la distribución de las ocupadas y los ocupados por ocupaciones y por sectores; en segundo lugar se analiza el crecimiento del empleo en las ocupaciones y en los sectores calificados como de “femeninos” o “masculinos”; en tercer lugar se calculan los índices de disimilitud (ID) para ocupaciones y sectores (a dos dígitos) y se estudia su evolución a lo largo de los últimos años; en cuarto lugar, se muestran los ID de ocupaciones según edad, nivel de formación, sector y comunidad autónoma; finalmente, el trabajo se cierra con un apartado dedicado a conclusiones

Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in Spain

Older age and cardiovascular comorbidities are well-known risk factors for all-cause mortality in patients with coronavirus disease 2019 (COVID-19). Hypertension and age are the 2 principal determinants of arterial stiffness (AS). This study aimed to estimate AS in patients with COVID-19 requiring hospitalization and analyze its association with all-cause in-hospital mortality. This observational, retrospective, multicenter cohort study analyzed 12 170 patients admitted to 150 Spanish centers included in the SEMI-COVID-19 Network. We compared AS, defined as pulse pressure ≥60 mm Hg, and clinical characteristics between survivors and nonsurvivors. Mean age was 67.5 (±16.1) years and 42.5% were women. Overall, 2606 (21.4%) subjects died. Admission systolic blood pressure (BP) <120 and ≥140 mm Hg was a predictor of higher all-cause mortality (23.5% and 22.8%, respectively, P<0.001), compared with systolic BP between 120 and 140 mm Hg (18.6%). The 4379 patients with AS (36.0%) were older and had higher systolic and lower diastolic BP. Multivariate analysis showed that AS and systolic BP <120 mm Hg significantly and independently predicted all-cause in-hospital mortality (adjusted odds ratio [ORadj]: 1.27, P=0.0001; ORadj: 1.48, P=0.0001, respectively) after adjusting for sex (males, ORadj: 1.6, P=0.0001), age tertiles (second and third tertiles, ORadj: 2.0 and 4.7, P=0.0001), Charlson Comorbidity Index (second and third tertiles, ORadj: 4.8 and 8.6, P=0.0001), heart failure, and previous and in-hospital antihypertensive treatment. Our data show that AS and admission systolic BP <120 mm Hg had independent prognostic value for all-cause mortality in patients with COVID-19 requiring hospitalization

Transferencia de los resultados de Trabajos Fin de Grado y Máster a la docencia -TF-Transfer

Depto. de GeografíaFac. de Geografía e HistoriaFALSEsubmitte

Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP

Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn´s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014–2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 ± 2.5 years. The median EEN duration was 8 weeks (IQR 6.6–8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn’s Disease activity index [wPCDAI] 15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6–8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn’s disease regardless of the location of disease and disease activityS

Cross-disease Meta-analysis of Genome-wide Association Studies for Systemic Sclerosis and Rheumatoid Arthritis Reveals IRF4 as a New Common Susceptibility Locus

Objectives: Systemic sclerosis (SSc) and rheumatoid arthritis (RA) are autoimmune diseases that share clinical and immunological characteristics. To date, several shared SSc- RA loci have been identified independently. In this study, we aimed to systematically search for new common SSc-RA loci through an inter-disease meta-GWAS strategy. Methods: We performed a meta-analysis combining GWAS datasets of SSc and RA using a strategy that allowed identification of loci with both same-direction and opposingdirection allelic effects. The top single-nucleotide polymorphisms (SNPs) were followed-up in independent SSc and RA case-control cohorts. This allowed us to increase the sample size to a total of 8,830 SSc patients, 16,870 RA patients and 43,393 controls. Results: The cross-disease meta-analysis of the GWAS datasets identified several loci with nominal association signals (P-value < 5 x 10-6), which also showed evidence of association in the disease-specific GWAS scan. These loci included several genomic regions not previously reported as shared loci, besides risk factors associated with both diseases in previous studies. The follow-up of the putatively new SSc-RA loci identified IRF4 as a shared risk factor for these two diseases (Pcombined = 3.29 x 10-12). In addition, the analysis of the biological relevance of the known SSc-RA shared loci pointed to the type I interferon and the interleukin 12 signaling pathways as the main common etiopathogenic factors. Conclusions: Our study has identified a novel shared locus, IRF4, for SSc and RA and highlighted the usefulness of cross-disease GWAS meta-analysis in the identification of common risk loci

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

Altres ajuts: Fondo Europeo de Desarrollo Regional (FEDER), "A way of making Europe".Copy number (CN) polymorphisms of complement C4 play distinct roles in many conditions, including immune-mediated diseases. We investigated the association of C4 CN with systemic sclerosis (SSc) risk. Imputed total C4, C4A, C4B, and HERV-K CN were analyzed in 26,633 individuals and validated in an independent cohort. Our results showed that higher C4 CN confers protection to SSc, and deviations from CN parity of C4A and C4B augmented risk. The protection contributed per copy of C4A and C4B differed by sex. Stronger protection was afforded by C4A in men and by C4B in women. C4 CN correlated well with its gene expression and serum protein levels, and less C4 was detected for both in SSc patients. Conditioned analysis suggests that C4 genetics strongly contributes to the SSc association within the major histocompatibility complex locus and highlights classical alleles and amino acid variants of HLA-DRB1 and HLA-DPB1 as C4-independent signals

Global data on earthworm abundance, biomass, diversity and corresponding environmental properties

Publisher Copyright: © 2021, The Author(s).Earthworms are an important soil taxon as ecosystem engineers, providing a variety of crucial ecosystem functions and services. Little is known about their diversity and distribution at large spatial scales, despite the availability of considerable amounts of local-scale data. Earthworm diversity data, obtained from the primary literature or provided directly by authors, were collated with information on site locations, including coordinates, habitat cover, and soil properties. Datasets were required, at a minimum, to include abundance or biomass of earthworms at a site. Where possible, site-level species lists were included, as well as the abundance and biomass of individual species and ecological groups. This global dataset contains 10,840 sites, with 184 species, from 60 countries and all continents except Antarctica. The data were obtained from 182 published articles, published between 1973 and 2017, and 17 unpublished datasets. Amalgamating data into a single global database will assist researchers in investigating and answering a wide variety of pressing questions, for example, jointly assessing aboveground and belowground biodiversity distributions and drivers of biodiversity change.Peer reviewe

Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism

Background Atrial fibrillation (AF) may exist before or occur early in the course of pulmonary embolism (PE). We determined the PE outcomes based on the presence and timing of AF. Methods and Results Using the data from a multicenter PE registry, we identified 3 groups: (1) those with preexisting AF, (2) patients with new AF within 2 days from acute PE (incident AF), and (3) patients without AF. We assessed the 90-day and 1-year risk of mortality and stroke in patients with AF, compared with those without AF (reference group). Among 16 497 patients with PE, 792 had preexisting AF. These patients had increased odds of 90-day all-cause (odds ratio [OR], 2.81; 95% CI, 2.33-3.38) and PE-related mortality (OR, 2.38; 95% CI, 1.37-4.14) and increased 1-year hazard for ischemic stroke (hazard ratio, 5.48; 95% CI, 3.10-9.69) compared with those without AF. After multivariable adjustment, preexisting AF was associated with significantly increased odds of all-cause mortality (OR, 1.91; 95% CI, 1.57-2.32) but not PE-related mortality (OR, 1.50; 95% CI, 0.85-2.66). Among 16 497 patients with PE, 445 developed new incident AF within 2 days of acute PE. Incident AF was associated with increased odds of 90-day all-cause (OR, 2.28; 95% CI, 1.75-2.97) and PE-related (OR, 3.64; 95% CI, 2.01-6.59) mortality but not stroke. Findings were similar in multivariable analyses. Conclusions In patients with acute symptomatic PE, both preexisting AF and incident AF predict adverse clinical outcomes. The type of adverse outcomes may differ depending on the timing of AF onset.info:eu-repo/semantics/publishedVersio